


## **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

1. (Currently Amended) A compound of formula (I)



R is halogen, C<sub>1-4</sub> alkyl, cyano, C<sub>1-4</sub> alkoxy, trifluoromethyl or trifluoromethoxy;  
R<sub>1</sub> is hydrogen, halogen, C<sub>3-7</sub>cycloalkyl, hydroxy, nitro, cyano or C<sub>1-4</sub> alkyl optionally substituted by halogen, cyano or C<sub>1-4</sub> alkoxy;

R<sub>2</sub> is hydrogen or C<sub>1-4</sub> alkyl;

R<sub>3</sub> and R<sub>4</sub> independently are hydrogen, cyano, C<sub>1-4</sub> alkyl or R<sub>3</sub> together with R<sub>4</sub> and the carbon to which they are bonded form a C<sub>3-7</sub> cycloalkyl;

R<sub>5</sub> is trifluoromethyl, S(O)<sub>t</sub> C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, trifluoromethoxy, halogen or cyano;

R<sub>6</sub> is hydrogen or (CH<sub>2</sub>)<sub>r</sub>R<sub>7</sub>;

R<sub>7</sub> is hydrogen, C<sub>3-7</sub> cycloalkyl, NH(C<sub>1-4</sub>alkylOC<sub>1-4</sub>alkoxy), NH(C<sub>1-4</sub>alkyl), N(C<sub>1-4</sub>alkyl)<sub>2</sub>, OC(O)NR<sub>9</sub>R<sub>8</sub>, NR<sub>8</sub>C(O)R<sub>9</sub> or C(O)NR<sub>9</sub>R<sub>8</sub>;

R<sub>9</sub> and R<sub>8</sub> independently are hydrogen, C<sub>1-4</sub> alkyl or C<sub>3-7</sub> cycloalkyl;

m is zero or an integer from 1 to 4;

n is 1 or 2;

p is zero or an integer from 1 to 3;

q is an integer from 1 to 3;

r is an integer from 1 to 4;

t is 0, 1 or 2;

provided that when m is 0, p is 2, q, r and n is 1, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>7</sub> are hydrogen and R is chlorine, then R<sub>5</sub> is not iodine;

or a pharmaceutically acceptable salt or solvate thereof.

- 2 (Previously presented) A compound as claimed in claim 1 wherein R is halogen, cyano, trifluoromethyl or a C<sub>1-4</sub> alkyl and p is 0 or an integer from 1 to 2.

3. (Previously presented) A compound as claimed in claim 1 wherein  $R_5$  is trifluoromethyl, cyano, methyl or halogen and  $q$  is an integer from 1 to 2.
4. (Previously presented) A compound as claimed in claim 1 wherein  $R_6$  is hydrogen or  $(CH_2)_r R_7$  in which  $r$  is 1 or 2 and  $R_7$  is hydrogen, cyclopropyl,  $C(O)N(C_{1-4} \text{ alkyl})_2$ ,  $C(O)NH(C_{1-4} \text{ alkyl})$  or  $C_{1-4}$  alkoxy.
5. (Currently Amended) A compound as claimed in claim 1 wherein  $R$  is  $C_{1-4}$  alkyl, halogen, trifluoromethyl or cyano;  $R_1$  is hydrogen, methyl, ethyl or halogen,  $R_2$  is a methyl or hydrogen,  $R_3$  and  $R_4$  are independently hydrogen or methyl,  $R_5$  is trifluoromethyl, cyano, methyl, chlorine, bromine or fluorine,  $R_6$  is hydrogen, methyl, ethyl methylcyclopropyl  $(CH_2)_2OCH_3$  or  $CH_2C(O)N(CH_3)_2$ ,  $p$  is 0 or an integer from 1 to 2,  $m$  is 0 or 1,  $n$  is 1 or 2, and  $q$  is 1 or 2.
6. (Previously presented) A compound as claimed in claim 1 wherein  $m$  is 1.
7. (Previously presented) A compound selected from:  
N-(3,5-Dichlorobenzyl)-2-[4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide;  
N-(3,5-Dichlorobenzyl)-2-[3-fluoro-4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide ;  
4-(4-Fluorophenyl)-piperidine-4-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;  
4-(4-Chlorophenyl)-piperidine-4-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;  
4-(4-Fluorophenyl)-piperidine-4-carboxylic acid (3,5-dichloro-benzyl)-methylamide;  
N-(3,5-Bis-trifluoromethyl)-benzyl-2-[(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-N-methyl-acetamide;  
N-(3,5-Dichlorobenzyl)-2-[4-(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-N-methyl-acetamide;  
N-(3,5-Bis-trifluoromethyl-benzyl)-2-[4-(4-fluorophenyl)-azepin-4-yl]-N-methyl-acetamide;  
N-(3,5-Bis-trifluoromethyl-benzyl)-2-[4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;  
N-(3,5-Dichlorobenzyl)-2-[4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;  
N-(3,5-Bis-trifluoromethyl-benzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Dichlorobenzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Dichlorobenzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Bis-trifluoromethyl-benzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Dibromobenzyl)-2-[4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-(3,5-Dibromo-benzyl)-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

N-(3,5-Dibromobenzyl)-2-(4-phenyl-piperidin-4-yl)-N-methyl-acetamide;

N-(3,5-Dibromo-benzyl)-2-(4-phenyl-1-methyl-piperidin-4-yl)-N-methyl-acetamide;

N-[1-(3,5-Dichloro-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Dichloro-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-(4-phenyl-piperidin-4-yl)-N-methyl-acetamide;

N-[1-(3,5- Bis-trifluoromethyl-phenyl)-ethyl]-2-(4-phenyl-1-methyl-piperidin-4-yl)-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-(4-phenyl-piperidin-4-yl)-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-(4-phenyl-1-methyl-piperidin-4-yl)-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

N-[(3,5-Dichlorophenyl)methyl]-2-{4-(4-fluoro-2-methylphenyl)-1-[2-(methyloxy)ethyl]-4-piperidiny]-N-methylacetamide;

*N*-{1-[3,5-Bis(trifluoromethyl)phenyl]ethyl}-2-[4-(4-fluoro-2-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;

*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;

*N*-{[3,5-Bis(trifluoromethyl)phenyl]methyl}-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

*N*-[(3,5-Dichlorophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

*N*-{[3,5-Bis(trifluoromethyl)phenyl]methyl}-2-[4-(4-fluoro-2-methylphenyl)-4-piperidinyl]acetamide;

*N*-{[3,5-Bis(trifluoromethyl)phenyl]methyl}-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidinyl]acetamide;

*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

*N*-[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-[4-(2-methylphenyl)-4-piperidinyl]acetamide;

*N*-[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-[1-methyl-4-(2-methylphenyl)-4-piperidinyl]acetamide;

*N*-[(3,5-Dichlorophenyl)methyl]-2-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

*N*-{[3,5-Bis(trifluoromethyl)phenyl]methyl}-2-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

*N*-[1-(3,5-Dibromophenyl)-1-methylethyl]-2-[4-(4-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide;

*N*-[1-(3,5-Dibromophenyl)-1-methylethyl]-2-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

*N*-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-*N*-methylacetamide ;

*N*-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-*N*-methyl-acetamide;

2-[1-(Cyclopropylmethyl)-4-(4-fluorophenyl)-4-piperidinyl]-*N*-[(3,5-dibromophenyl)methyl]-*N*-methylacetamide;

2-[4-{2-[[[(3,5-Dibromophenyl)methyl](methyl)amino]-2-oxoethyl]-4-(4-fluorophenyl)-1-piperidinyl]-*N,N*-dimethylacetamide;

*N*-[(3,5-Dibromophenyl)methyl]-2-[1-ethyl-4-(4-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide;

*N*-{1-[3,5-Bis(trifluoromethyl)phenyl]ethyl}-2-[4-(4-fluorophenyl)hexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;

*N*-{1-[3,5-Bis(trifluoromethyl)phenyl]ethyl}-2-[4-(4-fluorophenyl)-1-methylhexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;

*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluorophenyl)hexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;

*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluorophenyl)-1-methylhexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;

*N*-[(3-Bromo-5-cyanophenyl)methyl]-2-[4-(4-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide;

*N*-[(3-Bromo-5-cyanophenyl)methyl]-2-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

*N*-[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-{4-[3-(trifluoromethyl)phenyl]-4-piperidinyl}acetamide;

*N*-[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-{1-methyl-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl}acetamide;

*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(3,4-dimethylphenyl)-4-piperidinyl]-*N*-methylacetamide;

*N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

*N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;

*N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

2-[4-(3-Chlorophenyl)-4-piperidinyl]-*N*-[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;

*N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3,4-difluorophenyl)-4-piperidinyl]-*N*-methylacetamide;

*N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3,4-difluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

*N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide ;

*N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

*N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;

*N*-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;


2-[4-(3-Chlorophenyl)-4-piperidinyl]-*N*-[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;

2-[4-(3-Chlorophenyl)-1-methyl-4-piperidinyl]-*N*-[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;

2-[4-(3-Chlorophenyl)-4-piperidinyl]-*N*-[1-(3,5-dichlorophenyl)ethyl]-*N*-methylacetamide;  
2-[4-(3-Chlorophenyl)-1-methyl-4-piperidinyl]-*N*-[1-(3,5-dichlorophenyl)ethyl]-*N*-methylacetamide;  
2-[4-(3-Chlorophenyl)-4-piperidinyl]-*N*-[(3,5-dibromophenyl)methyl]-*N*-methylacetamide;  
*N*-[1-(3,5-Dichlorophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;  
*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;  
*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-3-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide ;  
*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(3-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide;  
*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(3-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;  
*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(3,4-difluorophenyl)-4-piperidinyl]-*N*-methylacetamide;  
*N*-[(3,5-Dibromophenyl)methyl]-2-[4-(3,4-difluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;  
2-[4-(4-Cyanophenyl)-4-piperidinyl]-*N*-[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;  
diastereoisomers or enantiomers thereof and pharmaceutically acceptable salts thereof  
.

8 (Previously presented) A compound selected from  
[*N*-(3,5-Dibromo-benzyl)-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-*N*-methylacetamide;  
*N*-[1-(*S*)-1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-*N*-methylacetamide;  
*N*-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-*N*-methylacetamide (enantiomer 1);  
*N*-[1-(3,5-Dibromo-phenyl)-ethyl]-2-(1-methyl-4-phenyl-piperidin-4-yl)-*N*-methylacetamide (enantiomer 1);  
*N*-[1-(3,5-Dichloro-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-*N*-methylacetamide (enantiomer 1);  
and pharmaceutically acceptable salts thereof.

9. (Previously presented) A process (A) for the preparation of a compound as claimed in claim 1 which comprises reacting an activated derivative of the carboxylic acid of formula (II) wherein R<sub>6</sub> is a nitrogen protecting group or (CH<sub>2</sub>)<sub>r</sub>R<sub>7</sub>, with amine (III)



wherein  $R_2$  is hydrogen,  $C_{1-4}$  alkyl or a nitrogen protecting group, followed where necessary by removal of any nitrogen protecting group.

10-12. (Canceled)


13. (Previously presented) A pharmaceutical composition comprising a compound as claimed in claim 1 in admixture with one or more pharmaceutically acceptable carriers or excipients.

14. (Canceled)

15. (Previously presented) A compound as claimed in claim 1 wherein  $R$  is fluorine or chlorine, cyano, trifluoromethyl or methyl and  $p$  is 0 or an integer from 1 to 2.

16. (Currently Amended) A compound as claimed in claim 1 wherein  $R$  is  $C_{1-4}$  alkyl, chlorine or fluorine, trifluoromethyl or cyano;  $R_1$  is hydrogen, methyl, ethyl or fluorine,  $R_2$  is a methyl or hydrogen,  $R_3$  and  $R_4$  are independently hydrogen or methyl,  $R_5$  is trifluoromethyl, cyano, methyl, chlorine, bromine or fluorine,  $R_6$  is hydrogen, methyl, ethyl methylcyclopropyl  $(CH_2)_2OCH_3$  or  $CH_2C(O)N(CH_3)_2$ ,  $p$  is 0 or an integer from 1 to 2,  $m$  is 0 or 1,  $n$  is 1 or 2, and  $q$  is 1 or 2.

17. (Previously presented) A process (B) for the preparation of a compound as claimed in claim 1 wherein  $R_2$  is  $C_{1-4}$  alkyl comprising reacting a compound of formula (Ia), with  $(C_{1-4} \text{ alkyl})L$  wherein  $L$  is a suitable leaving group selected from iodine, bromine



18. (Withdrawn) A method for the treatment of a condition mediated by a tachykinin and/or selective inhibition of serotonin reuptake transporter protein in a mammal in need thereof, comprising administering an effective amount of a compound as claimed in claim 1.
19. (Withdrawn) The method as claimed in claim 18, wherein said tachykinin is substance P.
20. (Withdrawn) The method as claimed in claim 18, wherein said mammal is man.